TY - JOUR
T1 - Imipramine binding to platelets of children with attention deficit disorder with hyperactivity
AU - Weizman, Abraham
AU - Bernhout, Edna
AU - Weitz, Raphael
AU - Tyano, Sam
AU - Rehavi, Moshe
N1 - Funding Information:
From Geha Psychiatric Hospital (A.W.. E.B., S.T.). Belinson Medical Center (R.W.), and Department of Physiology and Phanmcology (M.R.), Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel. Supported by a grant from the Mordechai Ofer Foundation. Address reprint requests to Dr. Moseh Rehavi, Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv 69978, Israel. Received February 28, 1987; revised June 25, 1987.
PY - 1988/3/1
Y1 - 1988/3/1
N2 - High-affinity [3H]imipramine binding to platelets was investigated in 11 boys with attention deficit disorder and hyperactivity (ADDH) before and after 28 days of methylphenidate (MPH) treatment, and the results were compared to [3H] imipramine binding parameters (Kd, Bmax) of 10 age-matched normal boys. The binding parameters for imipramine binding sites did not differ between ADDH children and controls. Moreover, the beneficial therapeutic effect of MPH was not accompanied by any alteration in the binding values. This study is consistent with other studies that failed to demonstrate involvement of the serotonergic system in the pathophysiology of ADDH and in the therapeutic effect of MPH.
AB - High-affinity [3H]imipramine binding to platelets was investigated in 11 boys with attention deficit disorder and hyperactivity (ADDH) before and after 28 days of methylphenidate (MPH) treatment, and the results were compared to [3H] imipramine binding parameters (Kd, Bmax) of 10 age-matched normal boys. The binding parameters for imipramine binding sites did not differ between ADDH children and controls. Moreover, the beneficial therapeutic effect of MPH was not accompanied by any alteration in the binding values. This study is consistent with other studies that failed to demonstrate involvement of the serotonergic system in the pathophysiology of ADDH and in the therapeutic effect of MPH.
UR - http://www.scopus.com/inward/record.url?scp=0023851984&partnerID=8YFLogxK
U2 - 10.1016/0006-3223(88)90021-2
DO - 10.1016/0006-3223(88)90021-2
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0023851984
SN - 0006-3223
VL - 23
SP - 491
EP - 496
JO - Biological Psychiatry
JF - Biological Psychiatry
IS - 5
ER -